Economic Burden and Provider Referral Patterns Among Patients with Unresectable Stage III EGFR-Mutated NSCLC Receiving Chemoradiotherapy in the United States
Patients with unresectable stage III EGFRm NSCLC incur substantial economic burden, especially in ambulatory HCRU and costs. With the recent approval of targeted treatment for these patients, reflex EGFRm testing in all early-stage NSCLC at diagnosis is encouraged. Our results also suggest MDT involvement may improve completeness in diagnosis and staging, resulting in acceleration of treatment planning and management.
Authors
- Arber Shehu (ORCID: https://orcid.org/0000-0002-0196-2960)
- Kim C. Ohaegbulam (ORCID: https://orcid.org/0000-0002-0498-3708)
- Mary DuCharme (ORCID: https://orcid.org/0009-0000-1372-8525)
- Yong-Jin Kim (ORCID: https://orcid.org/0000-0002-3055-9943)
- Kristin J. Moore (ORCID: https://orcid.org/0000-0003-2179-6565)
- Dan James
- Zhu Yong
- Yanique Rattigan-Brown
Institutions
- Oregon Health & Science University (US)
- Polaris (United States) (US)
- Optum (United States) (US)
- AstraZeneca (Canada) (CA)
- AstraZeneca (United States) (US)
Publication Details
- Journal
- Advances in Therapy
- Published
- 2025-05-29
- DOI
- https://doi.org/10.1007/s12325-025-03239-y
- Citations
- 1
- Primary Topic
- Lung Cancer Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 1.52
Funders
- AstraZeneca